Welcome to our dedicated page for Royalty Pharma plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma under Rule 144. These shares, acquired in private transactions in 2024 and 2025, have an aggregate market value of $6,012,000. Royalty Pharma had 445,277,344 shares outstanding as of the notice date. SCH Investment Partners LLC previously sold 150,000 shares for $8,166,766.13 on June 23, 2026 and 100,000 shares for $5,645,700.97 on June 30, 2026, all under a selling plan dated March 20, 2026 intended to comply with Rule 10b5-1(c).
Royalty Pharma plc major shareholder Pablo Legorreta filed an amended beneficial ownership report updating his holdings in the company’s Class A ordinary shares. Pablo Legorreta is reported as beneficially owning 101,785,843 Class A Shares, representing 18.73% of the class, including 96,873,648 shares that may be issued under an A&R Exchange Agreement. Legorreta Investments, LLC is reported as beneficially owning 37,535,019 Class A Shares, representing 7.76%, including 37,074,880 shares that may be issued under the same agreement. These percentages are calculated based on 446,619,215 Class A Shares outstanding as of August 13, 2026, plus shares issuable pursuant to the A&R Exchange Agreement.
The filing explains that SEC rules attribute beneficial ownership to persons with sole or shared voting or investment power and include Class A Shares issuable upon conversion or exercise of other securities that are immediately, or within 60 days, convertible or exercisable. It also describes recent equity-related activity, including the settlement of equity performance awards and a bona fide gift of partnership interests exchangeable into Class A Shares.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported selling a total of 11,002 Class A Ordinary Shares of RPRX on August 13, 2026 in open-market or private transactions under a Rule 10b5-1 plan adopted on February 24, 2026. The sales comprised 9,230 shares at a weighted average price of $58.5864 (with individual trades between $57.99 and $58.98) and 1,772 shares at a weighted average price of $59.1415 (with trades between $58.98 and $59.52). Following these transactions, indirect holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in the reporting person’s IRA, and 1,450 shares held by the spouse, plus 1,500 shares held directly. In addition, the reporting person and related family vehicles hold interests exchangeable into 6,448,180 Class A Ordinary Shares via limited partnership interests in RPI US Partners 2019, LP and 1,788,777 Class A Ordinary Shares via Class E Ordinary Shares of Royalty Pharma Holdings Ltd, which are subject to vesting conditions.
TPC RP EPA1 LLC, an affiliate stockholder of Royalty Pharma plc (symbol RPRX), filed a notice of proposed sale of 11,002 shares of common stock through Goldman Sachs & Co. LLC. The shares were acquired on 08/05/2026 as compensation under performance awards from the issuer.
The filing also lists a prior transaction in the last three months, where TPC RP EPA1 LLC sold 64,399 shares of common stock on 05/26/2026 for an aggregate amount of $3,476,118.96.
Royalty Pharma plc (ticker RPRX) filed notice of a proposed sale of up to 11,925,082 Class A ordinary shares through J.P. Morgan Securities LLC on NASDAQ. The shares were acquired over time, including 125,000 shares from a Conversion of LP Interests on August 7, 2026 and multiple smaller grants received as compensation from the issuer between June 30, 2021 and May 13, 2026.
A shareholder of RPRX filed to potentially sell 125,000 Class A ordinary shares through broker J.P. Morgan Securities LLC on or after August 12, 2026, listed on NASDAQ. The filing notes the planned sale relates to a Conversion of LP Interests dated August 7, 2026.
The shares have an indicated aggregate market value of 7,223,750, while the issuer reports 445,277,344 Class A ordinary shares outstanding. This notice outlines an intention to sell; it does not confirm that any sale has occurred.
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma, reported an exempt award of 65,216 Class A Ordinary Shares in settlement of Equity Performance Awards, bringing his direct Class A stake to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares; these limited partnership interests may be exchanged into Class A at no additional cost under an exchange agreement. The filing also notes substantial indirect holdings through family entities and trusts, including 9,700,000 Class B and 13,356,742 Class E shares that are exchangeable into Class A, with Class E subject to vesting conditions.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported two equity changes. On August 5, 2026, an exempt acquisition under Rule 16b-3 delivered 11,002 Class A Ordinary Shares through settlement of Equity Performance Awards to TPC RP EPA1 LLC. On August 7, 2026, an indirect bona fide gift transferred 18,500 Class E Ordinary Shares, leaving 1,788,777 Class E shares indirectly held; these Class E shares are subject to vesting and are ultimately convertible into Class A Ordinary Shares. Coyne and related vehicles also hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares, plus additional direct and indirect Class A positions.
Hite Christopher reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc executive Christopher Hite, EVP & Chairman, Partnering, received an exempt grant of 11,002 Class A Ordinary Shares on 2026-08-05 in connection with settlement of Equity Performance Awards, held indirectly through SCH Investment Partners LLC, bringing that entity’s holdings to 470,401 shares. He also holds 40,000 Class A Ordinary Shares directly, while family vehicles controlled by him hold limited partnership interests exchangeable into 866,410 additional Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, which are subject to vesting conditions.
Royalty Pharma plc executive Urist Marshall reported two insider equity movements. He received 8,252 Class A Ordinary Shares as an exempt award tied to Equity Performance Awards and indirectly made a bona fide gift of 3,000 limited partnership interests exchangeable into 30,000 Class A shares. He also holds Class A shares indirectly through an IRA and Class E Ordinary Shares that are exchangeable into 1,356,528 Class A shares, subject to vesting conditions.